Phase II Trial of All-Trans Retinoic Acid in Metastatic Non-Small Cell Lung Cancer

References

• Rapp E., Pater J. L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer—Report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633–641
   PubMed Web of Science ®Google Scholar
• Souquet P. J., Chauvin F., Boissel J. P., et al. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 1993; 342: 19–21
   PubMed Web of Science ®Google Scholar
• Bollag W. Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumors. Int J Vitamin Res 1990; 40: 299–314
   Google Scholar
• Bollag W. Retinoids and cancer. Cancer Chemother Pharmacol 1979; 3: 207–215
   PubMed Web of Science ®Google Scholar
• Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem Biophys Acta 1980; 605: 33–91
   PubMed Web of Science ®Google Scholar
• Sporn M. B., Dunlop N. M., Newton D. L., et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs. Fed Proc 1976; 35: 1332–1338
   PubMedGoogle Scholar
• Warrell R., Frankel S., Miller W., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-frans retinoic acid). N Engl J Med 1991; 324: 1385–1393
   PubMed Web of Science ®Google Scholar
• Yung W. KA, Scott C., Fischbach A. J., et al. All frans-retinoic acid: A phase II radiation therapy oncology group study (RTOG-9113) in patients with recurrent malignant astrocytoma. Proc ASCO 1994; 495(13)176
   Google Scholar
• Winer E., Sutton L., Petros W., et al. Phase II trial of all-trans retinoic acid (TRA) in patients (PTS) with metastatic breast cancer. Proc ASCO 1994; 46(13)61
   Google Scholar
• Athanasiadis I., Gradishar W., Sheehan T., et al. A phase II study of all-trans retinoic acid and interferon-alpha (IFN-α) in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 1994; 1090(13)330
   Google Scholar
• Grunberg S., Itri L. Phase II study of isoretinoin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 1987; 71(11)1097–1098
   PubMedGoogle Scholar
• Rinaldi D. A., Lippman S. M., Bums H. A., III, et al. 13–cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. Anticancer Drugs 1993; 4: 33–36
   PubMed Web of Science ®Google Scholar
• Arnold A., Ayoub J., Douglas L., et al. Phase II trial of 13 cis-retinoic acid plus interferon α in non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 306–309
   PubMed Web of Science ®Google Scholar
• Ryssel H. J., Brunner K. W., Bollag W. Die perorale anwendung von Vitamin A-saure bei leukoplakien, hyperkeratosen und plattenepithelkarzinomen. Schweiz Med Wochenschr 1971; 101: 1027–1030
   PubMedGoogle Scholar
• Lippman S. M., Meyskens F. L., Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987; 107: 499–502
   PubMed Web of Science ®Google Scholar
• Toma S., Palumbo R., Gustavino C., et al. Efficacy of the association of 13–cis-retinoic acid (13cRA) and interferon-α2a (IFNα2a) in cervical intraepithelial neoplasia (CIN II-III): A pilot study. Proc ASCO 1994; 815(13)258
   Google Scholar
• Evard J. P., Bollag W. Konservative hehandlung der rezidivierenden harnblasenpapillomatose mit Vitamin A-saure. Schweiz Med Wochenschr 1972; 102: 1880–1883
   PubMedGoogle Scholar
• Reynolds C., Mattlay K., Croose U., et al. Response of neuroblastoma bone marrow metastases to 13 cis-retinoic acid. Proc Am Soc Clin Oncol 1990; 9: 54
   Google Scholar
• Lippman S., Parkinson D., Itri L., et al. 13-cis-retinoic acid and interferon alpha-2a: Effective conbination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235–241
   PubMed Web of Science ®Google Scholar
• Lippman S., Kavanagh J., Paredes-Espinoza M., et al. 13-cis-retinoic acid plus interferon-alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241–245
   PubMed Web of Science ®Google Scholar
• Hong W., Lippman S., Itri L., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1991; 323: 795–801
   Web of Science ®Google Scholar
• Pastorino U., Infante M., Maioli M., et al. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol, 11: 1216–1216
   PubMed Web of Science ®Google Scholar
• Percy C., Horm J. W., Goffman T. E. Trends in histologic type of lung cancer. SEER Program, 1973–1981. Lung Cancer: Causes and Prevention, M. Mizell, P. Dorrea. Verlag, Chemie International, Deerfield Beach, FL 1984; 153
   Google Scholar
• Kurzrock R., Estey E., Talpaz M. All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993; 11: 1489–1495
   PubMed Web of Science ®Google Scholar
• Kahn M., Luginbuhl W., Gaines L., et al. Leucocytosis associated with all-trans retinoic acid treatment in metastatic non-small cell lung cancer. J Natl Cancer Inst 1992; 84: 1669
   PubMed Web of Science ®Google Scholar
• Lee J., Newman R., Lippman S., et al. Phase I evaluation of all-transretinoic acid in adults with solid tumors. J Clin Oncol 1993; 11: 959–966
   PubMed Web of Science ®Google Scholar
• Neel B., Gebert J., Moghal N., et al. Abnormalities in retinoic acid receptor beta (RAR beta) are common in human lung cancer. Lung Cancer 1990; 6(S6)199
   Google Scholar
• Gebert J. F., Moghal N., Frangioni J. V., et al. High frequency of retinoic acid receptor abnormalities in human lung cancer. Oncogene 1991; 6: 1859–1868, published erratum appears in Oncogene 7:821, 1992
   PubMed Web of Science ®Google Scholar
• Kok K., Osinga J., Carritt, et al. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 1987; 330: 578–581
   PubMed Web of Science ®Google Scholar
• Athanasiadis I. 1994, Personal communication
   Google Scholar
• Guchelaar H. J., Timmar-Bosscha H., Dam-Mairing A., et al. Enhancement of cisplatin and etoposide cytotoxicity after ail-trans retinoic acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer 1993; 55: 442–447
   PubMed Web of Science ®Google Scholar
• Brazzell R., Vane F., Ehmann C., et al. Pharmacokihetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 1983; 24: 695–702
   PubMed Web of Science ®Google Scholar
• Muindi J., Frankel S. R., Miller W. H., Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive decrease in plasma concentrations: Implications for relapse and “resistance” in acute promyelocytic leukemia. Blood 1992; 79: 299–303
   PubMed Web of Science ®Google Scholar
• Leo M. A., Iida S., Lieber C. S. Retinoic acid metabolism by a system reconstituted with cytochrome P-450. Arch Biochem Biophys 1984; 234: 305–312
   PubMed Web of Science ®Google Scholar
• Rigas J. R., Francis P. A., Muindi J. RF, et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993; 85: 1921–1926
   PubMed Web of Science ®Google Scholar
• Newman R. A., Lee J. S., Lippman S. M., et al. Phase I evaluation of all-trans-retinoic acid (TRA) combined with ketoconazole (KTC) in adults with solid tumors. Proc ASCO 1994; 367(13)143
   Google Scholar